Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Demand for weight loss jabs continues to surge, particularly as the NHS began offering Wegovy in late 2023 and will start offering ... as a pre-filled injection pen that is to be injected under the ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Buying shares of the right companies -- those that can generate generous returns for decades -- will help significantly ...

The company's forward yield is about 4%, while its cash payout ratio is conservative enough at just under ... market for weight loss drugs. The drugmaker's famous medicine, Wegovy, is one of ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.